Cascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
September 20 2017 - 9:00AM
Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage
biopharmaceutical company, today announced that management will
present at the Cantor Fitzgerald Global Healthcare Conference on
Wednesday, September 27, 2017, at 9:45 a.m. EDT / 6:45 a.m. PDT in
New York City.
A live audio webcast of the presentation will be available
through the “Events & Presentations” page of the “News &
Events” section of Cascadian Therapeutics’ website at
cascadianrx.com. An archived edition of the session will be
available later that day.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical
company dedicated to developing innovative product candidates for
the treatment of cancer. Its lead product candidate, tucatinib, is
an investigational oral, selective small molecule HER2 inhibitor.
Cascadian Therapeutics is conducting a randomized, double-blind,
controlled pivotal clinical trial called HER2CLIMB, which is
comparing tucatinib vs. placebo, each in combination with
capecitabine and trastuzumab, in patients with locally advanced or
metastatic HER2+ breast cancer with and without brain metastases,
who have previously been treated with trastuzumab, pertuzumab and
T-DM1. Additional details on HER2CLIMB can be found at
www.HER2CLIMB.com or www.clinicaltrials.gov. For more information,
please visit www.cascadianrx.com.
Investor and Media Contact:Monique
GreerCascadian Therapeutics206-801-2107mgreer@cascadianrx.com
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Apr 2023 to Apr 2024